A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
A Phase 1/2, Open Label, Multicenter, Multi-cohort Study of S241656 as Monotherapy or in Combination With Other Antileukemic Agents in Participants With Selected Myeloid Malignancies
The objective of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of S241656 and to determine the recommended dose for expansion (RDE) of S241656 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML), myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), or chronic myelomonocytic leukemia (CMML). Part 1A dose escalation will determine the RDE to be used in a future expansion stage of the trial. An optional Part 1B drug-drug interaction (DDI) substudy will evaluate the effect of posaconazole on the PK of S241656.
The study consists of a screening period of up to 21 days, a treatment period consisting of continuous 28-day cycles of treatment, an end-of-treatment visit, a safety follow-up period, and long-term disease and survival follow-up every 3 months. Participants in the optional DDI substudy may continue treatment in the main study following completion of the DDI assessment period. Participants may undergo bone marrow aspirates and/or biopsies, blood tests, electrocardiograms (ECGs), echocardiograms or multigated acquisition (MUGA) scans, physical examinations, ophthalmologic assessments, and disease response questionnaires.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Institut de Recherches Internationales Servier (I.R.I.S.)
- Telefonnummer: +33 1 55 72 60 00
- E-post: scientificinformation@servier.com
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
- Investigator-assessed life expectancy of ≥ 3 months.
- Able and willing to comply with requirements of the study protocol.
- Documented genetic characterization of the disease as per local practice.
- Clinical and laboratory thresholds:
- Cytoreduction: white blood cell (WBC) < 25 × 10⁹/L (hydroxyurea/cytarabine/leukapheresis allowed).
- Renal: creatinine clearance (CrCl) ≥ 60 mL/min (Cockcroft-Gault).
- Hepatic: aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN) (5 × if leukemic); Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN for Gilbert's syndrome).
- Part 1 Only: Relapsed/Refractory (R/R), pathologically confirmed AML, MDS/AML, or CMML.
- Part 1 Only: Must have failed ≥ 1 approved standard therapy and have no other approved standard options.
Exclusion Criteria:
- Known hypersensitivity to S241656, or Posaconazole (Part 1B).
- Pregnant or breastfeeding; positive serum pregnancy test for WOCBP.
- Diagnosis of acute promyelocytic leukemia (French-American-British [FAB] M3 classification), MPN, mixed/ambiguous lineage, histiocytic/dendritic cell neoplasms, or AML with isolated extramedullary disease (no marrow/blood involvement).
- Active Central Nervous System (CNS) disease (by cytologic or radiographic evidence).
- Failure to recover to ≤ Grade 1 from previous toxicities (except Grade 2 neuropathy/alopecia).
- Major surgery within 4 weeks.
- Any anticancer therapy within 2 weeks or 5 half-lives (28 days for biologics). Cytoreduction with hydroxyurea or cytarabine is permitted.
- Prior use of experimental KRAS/BRAF/MEK/ERK inhibitors (prior FLT3 inhibitors are permitted).
- Uncontrolled infections (human immunodeficiency virus (HIV)/hepatitis B virus (HBV)/hepatitis C virus (HCV) permitted only if viral load is undetectable/controlled and specific cluster of differentiation 4 (CD4)+ criteria are met).
- Malabsorption, Crohn's, or chronic vomiting that impacts oral drug absorption.
- History/risk of retinal vein occlusion (RVO), glaucoma, or hyper-viscosity syndromes.
- Other active malignancy requiring systemic therapy within 2 years (except non-melanoma skin cancer or localized/cured tumors).
- Stroke, myocardial infarction (MI), unstable angina, or acute coronary syndrome within 6 months.
- Congestive heart failure (CHF), clinically significant cardiac arrhythmias according to the investigator's judgement (e.g., ventricular tachycardia), complete left bundle branch block and high-grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II- and third degree AV block).
- Fridericia-corrected QT interval (QTcF) > 470 msec or history of Torsades de pointes.
- Disseminated intravascular coagulation (DIC), significant coagulopathy according to the investigator's judgement, or uncontrolled bleeding.
- Proton Pump Inhibitors (PPIs) and potassium-competitive acid blockers ≥ 7 days prior to Cycle 1 Day 1.
- Breast cancer resistance protein (BCRP) sensitive substrate or with a narrow therapeutic index (NTI)
- All herbal preparations/supplements are prohibited.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Part 1A: Dose Escalation
|
Tablets taken by mouth.
|
|
Eksperimentell: Part 1B: Optional Drug-Drug Interaction [DDI] Substudy
|
Tablets taken by mouth.
Tablets taken by mouth
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
(Part 1A and 1B) Dose limiting toxicity (DLTs) associated with S241656 during the first cycle of treatment
Tidsramme: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1A and 1B) Number of Adverse Events (AEs)
Tidsramme: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of Serious Adverse Events (SAEs)
Tidsramme: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Severity of AEs
Tidsramme: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Severity of SAEs
Tidsramme: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Duration of AEs
Tidsramme: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Duration of SAEs
Tidsramme: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of changes in safety laboratory results
Tidsramme: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of changes in physical examination
Tidsramme: Through 30 days after the last dose of treatment, up to approximately 4 years
|
Through 30 days after the last dose of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of dose reductions due to AEs
Tidsramme: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of dose interruptions due to AEs
Tidsramme: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of dose delays due to AEs
Tidsramme: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of study withdrawals due to AEs
Tidsramme: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1B only) Maximum concentration (Cmax) of S241656
Tidsramme: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) Cmax of metabolite S243796
Tidsramme: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) Time corresponding to Cmax (Tmax) of S241656
Tidsramme: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) Tmax of metabolite S243796
Tidsramme: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) Terminal half-life (t1/2) of S241656
Tidsramme: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) t1/2 of metabolite S243796
Tidsramme: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) Area under the curve (AUC) of S241656
Tidsramme: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
|
(Part 1B only) AUC of metabolite S243796
Tidsramme: Through Cycle 1 (28 days)
|
Through Cycle 1 (28 days)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
(Part 1A only) Cmax of S241656
Tidsramme: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) Cmax of metabolite S243796
Tidsramme: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) Tmax of S241656
Tidsramme: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) Tmax of metabolite S243796
Tidsramme: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) AUC of S241656
Tidsramme: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) AUC of metabolite S243796
Tidsramme: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) t1/2 of S241656
Tidsramme: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A only) t1/2 of metabolite S243796
Tidsramme: Through end of treatment, up to approximately 4 years
|
Through end of treatment, up to approximately 4 years
|
|
|
(Part 1A and 1B) Complete remission (CR)
Tidsramme: Through study completion, approximately 4 years
|
Through study completion, approximately 4 years
|
|
|
(Part 1A and 1B) Complete remission with incomplete hematologic recovery (CRi)
Tidsramme: Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Morphologic leukemia free state (MLFS)
Tidsramme: Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Complete remission with partial hematologic recovery (CRh)
Tidsramme: Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Partial response (PR)
Tidsramme: Through study completion, approximately 4 years
|
Through study completion, approximately 4 years
|
|
|
(Part 1A and 1B) Objective response (OR)
Tidsramme: Through study completion, approximately 4 years
|
Through study completion, approximately 4 years
|
|
|
(Part 1A and 1B) Composite complete remission (CRc)
Tidsramme: Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Red blood cell (RBC) and platelet transfusion independence for at least 8 weeks
Tidsramme: Through end of treatment, up to approximately 4 years
|
In participants with AML or MDS/AML only
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Duration of response (DOR)
Tidsramme: Through study completion, approximately 4 years
|
Through study completion, approximately 4 years
|
|
|
(Part 1A and 1B) Time to response (TTR)
Tidsramme: Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Event free survival (EFS)
Tidsramme: Through study completion, approximately 4 years
|
In participants with AML or MDS/AML only
|
Through study completion, approximately 4 years
|
|
(Part 1A and 1B) Overall survival (OS)
Tidsramme: Through study completion, approximately 4 years
|
Through study completion, approximately 4 years
|
|
|
(Part 1A and 1B) Marrow response
Tidsramme: Through end of treatment, up to approximately 4 years
|
In participants with CMML only
|
Through end of treatment, up to approximately 4 years
|
|
(Part 1A and 1B) Number of participants with erythroid-, neutrophil-, platelet or spleen-response
Tidsramme: Through end of treatment, up to approximately 4 years
|
In participants with CMML only
|
Through end of treatment, up to approximately 4 years
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Neoplasmer
- Kronisk sykdom
- Sykdomsattributter
- Genetiske sykdommer, medfødte
- Neoplasmer etter histologisk type
- Hematologiske sykdommer
- Leukemi, myeloid
- Myelodysplastiske-myeloproliferative sykdommer
- Benmargssykdommer
- Leukemi
- Myelodysplastiske syndromer
- Medfødte, arvelige og neonatale sykdommer og abnormiteter
- Patologiske tilstander, tegn og symptomer
- Hemic og lymfatiske sykdommer
- GATA2-mangel
- Leukemi, Myeloid, Akutt
- Leukemi, myelomonocytisk, kronisk
- posaconazol
Andre studie-ID-numre
Andre studie-ID-numre
- S241656-292
- 2025-525128-88-00 (Ctis)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.
Access can be requested for all interventional clinical studies:
- used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
- where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.
In addition, access can be requested for all interventional clinical studies in patients:
- sponsored by Servier
- with a first patient enrolled as of 1 January 2004 onwards
- for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.
IPD-delingstidsramme
Tilgangskriterier for IPD-deling
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .